14 hours ago
Hilaria Baldwin insists Alec Baldwin's gym skills are no match for hers!
The reality star spilled everything about the process to get her body back in shape and keep it that way, all while enjoying the pleasures of great meals within an acceptable boundary.
Hilaria Baldwin and Alec Baldwin tied the knot in June 2012, over a year after they met at a vegan restaurant in New York City. Through the course of their marriage, the couple has weathered intense media attention and controversies.
KAT / MEGA
The media personality noted that most of her routine thrives outside designated ****** es; instead, she achieves her quota through running every day and performing 30 minutes of cardio.
#baldwin #hilaria #city #Skills
The reality star spilled everything about the process to get her body back in shape and keep it that way, all while enjoying the pleasures of great meals within an acceptable boundary.
Hilaria Baldwin and Alec Baldwin tied the knot in June 2012, over a year after they met at a vegan restaurant in New York City. Through the course of their marriage, the couple has weathered intense media attention and controversies.
KAT / MEGA
The media personality noted that most of her routine thrives outside designated ****** es; instead, she achieves her quota through running every day and performing 30 minutes of cardio.
#baldwin #hilaria #city #Skills
4 days ago
On August 13, Capricor Therapeutics (NASDAQ:CAPR) held its second-quarter earnings call, just over two weeks after an FDA advisory committee voted 3 to 9 against the company's bid to treat cardiomyopathy in ****** nne muscular dystrophy patients on July 29. That rejection forced a strategic pivot. Management now plans to amend its Biologics License Application to pursue a narrower upper limb skeletal muscle indication, the same measure that carried the HOPE-3 trial's primary endpoint. The shift extends the regulatory timeline, but it also puts the spotlight back on the data that held up best.
Deramiocel's case still rests on real numbers. The HOPE-3 primary endpoint showed a statistically significant slowing of upper limb disease progression, with a 4.5% mean difference favoring the drug and a p-value of 0.029. During a separate advisory committee discussion, feedback on upper limb function was described as directionally supportive of that evidence. The cardiomyopathy subgroup's ejection fraction data held too, showing a 2.8 percentage point treatment difference at a p-value of 0.02, unchanged from the original ****** ysis.
Safety data spans more than 1,300 intravenous infusions across over 200 patients in three clinical trials, with more than 80 patients enrolled in open-label extension studies, some receiving infusions for over five years. The full HOPE-3 data set was published in The Lancet in July following independent peer review. The FDA has indicated it will review the coming BLA amendment and extend the PDUFA date accordingly, and Capricor has already opened regulatory conversations in Europe and ****** an while its manufacturing facility in San Diego remains operational for a potential launch.
The financial picture moved the other direction. Cash and marketable securities fell to $237.9 million as of June 30, 2026, down from $318.1 million at the end of 2025. Second quarter net loss widened to $40.7 million, or $0.70 per share, compared to $25.9 million, or $0.57 per share, a year earlier, as operating expenses climbed to $42.9 million from $27.7 million. Research and development spending rose to $28.9 million and general and administrative costs jumped to $14.1 million from $5.7 million. The company booked zero revenue again.
Complicating matters, the left ventricular ejection fraction result across all patients was revised under the prespecified statistical model from a 2.4 percentage point difference at p=0.04 down to 1.8 percentage points at p=0.09, weakening a key secondary measure. An FDA Bioresearch Monitoring inspection in July produced a Form 483 with one observation. Non-Deramiocel pipeline work remains on hold, and the company's arbitration with NS Pharma over their distribution agreement isn't expected to begin until fall 2026.
#limb
Deramiocel's case still rests on real numbers. The HOPE-3 primary endpoint showed a statistically significant slowing of upper limb disease progression, with a 4.5% mean difference favoring the drug and a p-value of 0.029. During a separate advisory committee discussion, feedback on upper limb function was described as directionally supportive of that evidence. The cardiomyopathy subgroup's ejection fraction data held too, showing a 2.8 percentage point treatment difference at a p-value of 0.02, unchanged from the original ****** ysis.
Safety data spans more than 1,300 intravenous infusions across over 200 patients in three clinical trials, with more than 80 patients enrolled in open-label extension studies, some receiving infusions for over five years. The full HOPE-3 data set was published in The Lancet in July following independent peer review. The FDA has indicated it will review the coming BLA amendment and extend the PDUFA date accordingly, and Capricor has already opened regulatory conversations in Europe and ****** an while its manufacturing facility in San Diego remains operational for a potential launch.
The financial picture moved the other direction. Cash and marketable securities fell to $237.9 million as of June 30, 2026, down from $318.1 million at the end of 2025. Second quarter net loss widened to $40.7 million, or $0.70 per share, compared to $25.9 million, or $0.57 per share, a year earlier, as operating expenses climbed to $42.9 million from $27.7 million. Research and development spending rose to $28.9 million and general and administrative costs jumped to $14.1 million from $5.7 million. The company booked zero revenue again.
Complicating matters, the left ventricular ejection fraction result across all patients was revised under the prespecified statistical model from a 2.4 percentage point difference at p=0.04 down to 1.8 percentage points at p=0.09, weakening a key secondary measure. An FDA Bioresearch Monitoring inspection in July produced a Form 483 with one observation. Non-Deramiocel pipeline work remains on hold, and the company's arbitration with NS Pharma over their distribution agreement isn't expected to begin until fall 2026.
#limb
5 days ago
I think David Tepper made a mistake selling UnitedHealth Group (NYSE: UNH), and not a small mistake either. When I look at what this company is doing and where healthcare is headed, I would rather buy the stock than walk away.
For context, here's what happened: Tepper is a billionaire hedge fund manager, the founder and president of Appaloosa Management. Tepper didn't trim his stake in UnitedHealth. He sold every share, about 90,000 in total, refocusing his portfolio toward artificial intelligence (AI) with purchases of Amazon (NASDAQ: AMZN), Micron (NASDAQ: MU), and Taiwan Semiconductor (NYSE: TSM), which now account for nearly 40% of his fund. That tells me his move was about concentrating on a narrower theme, not about UnitedHealth losing its edge. In earlier filings, UnitedHealth ranked among his top positions, accounting for more than 10% of the portfolio, indicating he once saw it as a core holding.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
So what changed? The obvious worry is medical cost pressure, especially from GLP‑1 weight loss drugs and broader inflation in care. UnitedHealth's Q2 2026 numbers show medical costs of $75.36 billion and a medical care ratio of 86.7%, down from 89.4% a year earlier but still above the mid-80s range the company had framed as its target (lower is better). Some investors see that as a sign that margins will stay under pressure and that insurers will never fully catch up to medical care's rising cost curve. Tepper may have decided that the headache was not worth the trouble.
When I dig into the details, I see something different. UnitedHealth is not sitting still and hoping costs fall. It's reshaping how care is delivered across its UnitedHealthcare insurance arm and Optum pharmacy management services. On GLP‑1 drugs, the company has drawn a clear line, covering them for diabetes and cardiovascular risk under tight medical necessity rules and restricting coverage for weight loss alone. It has launched programs like Total Weight Support to combine medication with coaching and digital tools, which gives it a way to manage outcomes rather than paying for pills without structure. That kind of strategy matters when drug costs can top $1,000 per member each month.
#medical #costs
For context, here's what happened: Tepper is a billionaire hedge fund manager, the founder and president of Appaloosa Management. Tepper didn't trim his stake in UnitedHealth. He sold every share, about 90,000 in total, refocusing his portfolio toward artificial intelligence (AI) with purchases of Amazon (NASDAQ: AMZN), Micron (NASDAQ: MU), and Taiwan Semiconductor (NYSE: TSM), which now account for nearly 40% of his fund. That tells me his move was about concentrating on a narrower theme, not about UnitedHealth losing its edge. In earlier filings, UnitedHealth ranked among his top positions, accounting for more than 10% of the portfolio, indicating he once saw it as a core holding.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
So what changed? The obvious worry is medical cost pressure, especially from GLP‑1 weight loss drugs and broader inflation in care. UnitedHealth's Q2 2026 numbers show medical costs of $75.36 billion and a medical care ratio of 86.7%, down from 89.4% a year earlier but still above the mid-80s range the company had framed as its target (lower is better). Some investors see that as a sign that margins will stay under pressure and that insurers will never fully catch up to medical care's rising cost curve. Tepper may have decided that the headache was not worth the trouble.
When I dig into the details, I see something different. UnitedHealth is not sitting still and hoping costs fall. It's reshaping how care is delivered across its UnitedHealthcare insurance arm and Optum pharmacy management services. On GLP‑1 drugs, the company has drawn a clear line, covering them for diabetes and cardiovascular risk under tight medical necessity rules and restricting coverage for weight loss alone. It has launched programs like Total Weight Support to combine medication with coaching and digital tools, which gives it a way to manage outcomes rather than paying for pills without structure. That kind of strategy matters when drug costs can top $1,000 per member each month.
#medical #costs
6 days ago
Zoetis Inc. (NYSE:ZTS) entered 2026 as a leader in animal health, but its latest earnings show that even a strong market position cannot fully insulate the company from weaker consumer demand. Fiscal Q2 2026 revenue remained flat at $2.5 billion and declined 1% on an organic operational basis, as pressure in the U.S. companion-animal market offset growth in livestock and international markets.
The quarter therefore presents investors with two different versions of Zoetis (NYSE:ZTS), as an established companion-animal business facing near-term pressure and a diversified animal-health platform still investing in its next generation of products.
Zoetis's (NYSE:ZTS) diversification provided an important source of resilience during the quarter. Livestock revenue increased 12% on a reported basis, supported by cattle and poultry products. In the United States, livestock sales grew 23% on both a reported and organic operational basis in the quarter, benefiting from favorable beef-cattle economics, supply timing, and increased poultry-vaccine sales **** ociated with disease outbreaks.
International performance was also encouraging. Revenue outside the United States rose 8% on a reported basis and 6% organically to $1.2 billion. International companion-animal sales grew 5% organically, supported by parasiticides such as Simparica Trio, Revolution and Stronghold, as well as diagnostics and newer osteoarthritis treatments. This geographic contrast demonstrates that the weakness was not uniform across Zoetis's (NYSE:ZTS) business. Demand for its products remains healthy in several markets, even as U.S. pet owners become more price-sensitive.
However, innovation could provide another route back to growth, as Zoetis (NYSE:ZTS) says that its pipeline contains more than 12 potential blockbuster candidates across chronic kidney disease, oncology, cardiology, anxiety, and obesity. The company also launched Lenivia and Portela, long-acting osteoarthritis treatments offering dogs and cats up to three months of pain relief from one injection.
#revenue #quarter
The quarter therefore presents investors with two different versions of Zoetis (NYSE:ZTS), as an established companion-animal business facing near-term pressure and a diversified animal-health platform still investing in its next generation of products.
Zoetis's (NYSE:ZTS) diversification provided an important source of resilience during the quarter. Livestock revenue increased 12% on a reported basis, supported by cattle and poultry products. In the United States, livestock sales grew 23% on both a reported and organic operational basis in the quarter, benefiting from favorable beef-cattle economics, supply timing, and increased poultry-vaccine sales **** ociated with disease outbreaks.
International performance was also encouraging. Revenue outside the United States rose 8% on a reported basis and 6% organically to $1.2 billion. International companion-animal sales grew 5% organically, supported by parasiticides such as Simparica Trio, Revolution and Stronghold, as well as diagnostics and newer osteoarthritis treatments. This geographic contrast demonstrates that the weakness was not uniform across Zoetis's (NYSE:ZTS) business. Demand for its products remains healthy in several markets, even as U.S. pet owners become more price-sensitive.
However, innovation could provide another route back to growth, as Zoetis (NYSE:ZTS) says that its pipeline contains more than 12 potential blockbuster candidates across chronic kidney disease, oncology, cardiology, anxiety, and obesity. The company also launched Lenivia and Portela, long-acting osteoarthritis treatments offering dogs and cats up to three months of pain relief from one injection.
#revenue #quarter
6 days ago
Medtronic plc (NYSE:MDT) and Tenet Healthcare Corporation (NYSE:THC) offer investors two very different healthcare growth stories. Medtronic's (NYSE:MDT) thesis rests on whether a new generation of medical devices can produce a durable turnaround across its enormous portfolio. Tenet (NYSE:THC), meanwhile, is generating stronger earnings by improving hospital profitability and focusing its ambulatory business on higher-acuity procedures.
The comparison ultimately comes down to whether investors prefer Medtronic's (NYSE:MDT) innovation-led recovery or Tenet's (NYSE:THC) stronger operating leverage.
Medtronic (NYSE:MDT) reported its highest annual revenue growth in a decade in its fiscal Q4 and full-year 2026 results, suggesting that years of investment in faster-growing technologies are beginning to produce meaningful results. Growth opportunities including Affera, Symplicity, Hugo, Altaviva, and Stealth AXiS give the company several potential drivers rather than leaving its recovery dependent on a single product.
Cardiac Ablation Solutions has emerged as a particularly important contributor. Revenue increased 78% globally, including 124% growth in the United States, as newer products strengthened Medtronic's (NYSE:MDT) position in the expanding cardiac-ablation market. The company is also investing in innovation and acquisitions, including targeted investments in intracardiac echocardiography catheter technology.
The breadth of Medtronic's (NYSE:MDT) pipeline supports the possibility that its recent acceleration can spread across more of the portfolio. Improving sentiment toward the wider medical-technology sector could provide an additional catalyst if the company maintains its execution. BTIG has argued that MedTech may be stabilizing following a period of underperformance, although company-specific results will ultimately matter more than broader sector sentiment.
#results #medtronic #healthcare
The comparison ultimately comes down to whether investors prefer Medtronic's (NYSE:MDT) innovation-led recovery or Tenet's (NYSE:THC) stronger operating leverage.
Medtronic (NYSE:MDT) reported its highest annual revenue growth in a decade in its fiscal Q4 and full-year 2026 results, suggesting that years of investment in faster-growing technologies are beginning to produce meaningful results. Growth opportunities including Affera, Symplicity, Hugo, Altaviva, and Stealth AXiS give the company several potential drivers rather than leaving its recovery dependent on a single product.
Cardiac Ablation Solutions has emerged as a particularly important contributor. Revenue increased 78% globally, including 124% growth in the United States, as newer products strengthened Medtronic's (NYSE:MDT) position in the expanding cardiac-ablation market. The company is also investing in innovation and acquisitions, including targeted investments in intracardiac echocardiography catheter technology.
The breadth of Medtronic's (NYSE:MDT) pipeline supports the possibility that its recent acceleration can spread across more of the portfolio. Improving sentiment toward the wider medical-technology sector could provide an additional catalyst if the company maintains its execution. BTIG has argued that MedTech may be stabilizing following a period of underperformance, although company-specific results will ultimately matter more than broader sector sentiment.
#results #medtronic #healthcare
8 days ago
Pfizer (NYSE: PFE) has an attractive 6.4% dividend yield. That compares to 1% for the S&P 500 index (SNPINDEX: ^GSPC) and 1.4% for the average pharmaceutical stock. Despite the outsize yield, the company is sticking by the dividend payment. That's great, but why is the yield so high? An examination of the business through 2030 will explain the problem.
From a big picture perspective, Pfizer sells pharmaceuticals. Only the drugs it sells don't appear out of thin air. It has to develop them or buy them before it can market them. That's an expensive, often time-consuming, and difficult process. This is why drug companies are afforded a limited, patent-protected window of exclusivity to sell their drugs. Drug companies like Pfizer can generate substantial revenue from patent-protected drugs.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
There's just one small problem: revenues tend to fall dramatically after a drug loses patent protections. Complicating this is that developing new drugs doesn't follow a set timeline, unlike patent expirations. So sometimes there's a mismatch that puts pressure on a company's top and bottom lines.
That's what Pfizer is dealing with right now. In 2027, oncology drugs Ibrance and Xtandi are set to lose patent protection. In 2028, the cardiovascular drug Eliquis will lose patent protection. Pfizer is working hard to find drugs to replace revenue lost from these patent expirations, but investors are clearly worried that it won't be able to. It doesn't help any that the company suffered a material black eye when it had to drop its internally developed GLP-1 weight-loss drug candidate in 2025.
#pfizer #drug #yield
From a big picture perspective, Pfizer sells pharmaceuticals. Only the drugs it sells don't appear out of thin air. It has to develop them or buy them before it can market them. That's an expensive, often time-consuming, and difficult process. This is why drug companies are afforded a limited, patent-protected window of exclusivity to sell their drugs. Drug companies like Pfizer can generate substantial revenue from patent-protected drugs.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
There's just one small problem: revenues tend to fall dramatically after a drug loses patent protections. Complicating this is that developing new drugs doesn't follow a set timeline, unlike patent expirations. So sometimes there's a mismatch that puts pressure on a company's top and bottom lines.
That's what Pfizer is dealing with right now. In 2027, oncology drugs Ibrance and Xtandi are set to lose patent protection. In 2028, the cardiovascular drug Eliquis will lose patent protection. Pfizer is working hard to find drugs to replace revenue lost from these patent expirations, but investors are clearly worried that it won't be able to. It doesn't help any that the company suffered a material black eye when it had to drop its internally developed GLP-1 weight-loss drug candidate in 2025.
#pfizer #drug #yield
10 days ago
Will this be the year that the tight end position finally lives up to its potential? For years we've hoped for a deep group of TEs riddled with talent at every draft point, only to end up with the same elite group and then a bunch of "Play and pray" options. But maybe this season will be different. Our Yahoo ****** ysts take a look at the tight end position and share their breakout candidate for 2026.
Breakouts tend to exist at the intersection of talent and situation. And for Brenton Strange, the talent piece of the equation isn't hard to see. Since joining the Jaguars in '23, Strange's routes and target share have been on an upward trajectory. The Penn State product barely saw the field his rookie season (2.2% target rate), but he evolved into one of Trevor Lawrence's go-to options as Jacksonville marched toward the playoffs.
After returning from a hip injury sustained in Week 5, Strange supplanted Brian Thomas Jr. as the "WR3" (16.6% share) and even led the team in red-zone targets (14). Plus, the added cardio has only allowed us to see more of his athletic ability, as his yards per route run (9th among all TEs in '25 – min. 10 games played) and YAC per reception picked up between Years 2 and 3.
But I'll admit Strange's situation is, well, strange! The Jaguars traded for and compensated Jakobi Meyers for bringing the passing game to life and got a breakout performance from their 6th-round WR out of the same draft class. Oh, and Thomas Jr. and Travis Hunter are still there. The "lot of mouths to feed" argument will keep Strange's draft-cost down, but let's not forget his productivity and utility within this offense. — Chris Allen
After the Rashid Shaheed trade, Johnson was the TE5 in yards per game and TE8 in receptions per game from Week 10 on. With Jordyn Tyson out until the Week 6-9 range, Johnson should start out strong, as this is the same Saints receiving corps as it was during that explosive sample. The Saints have the advantages of playing against the NFC South, playing indoors and operating in the No. 1 neutral pace offense. Johnson is also good! Watch him!
#strange
Breakouts tend to exist at the intersection of talent and situation. And for Brenton Strange, the talent piece of the equation isn't hard to see. Since joining the Jaguars in '23, Strange's routes and target share have been on an upward trajectory. The Penn State product barely saw the field his rookie season (2.2% target rate), but he evolved into one of Trevor Lawrence's go-to options as Jacksonville marched toward the playoffs.
After returning from a hip injury sustained in Week 5, Strange supplanted Brian Thomas Jr. as the "WR3" (16.6% share) and even led the team in red-zone targets (14). Plus, the added cardio has only allowed us to see more of his athletic ability, as his yards per route run (9th among all TEs in '25 – min. 10 games played) and YAC per reception picked up between Years 2 and 3.
But I'll admit Strange's situation is, well, strange! The Jaguars traded for and compensated Jakobi Meyers for bringing the passing game to life and got a breakout performance from their 6th-round WR out of the same draft class. Oh, and Thomas Jr. and Travis Hunter are still there. The "lot of mouths to feed" argument will keep Strange's draft-cost down, but let's not forget his productivity and utility within this offense. — Chris Allen
After the Rashid Shaheed trade, Johnson was the TE5 in yards per game and TE8 in receptions per game from Week 10 on. With Jordyn Tyson out until the Week 6-9 range, Johnson should start out strong, as this is the same Saints receiving corps as it was during that explosive sample. The Saints have the advantages of playing against the NFC South, playing indoors and operating in the No. 1 neutral pace offense. Johnson is also good! Watch him!
#strange
12 days ago
Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net return in the second quarter, indicating progress from the first quarter. Key changes to the portfolio will include lower concentration and increased investments with near-term catalysts, alongside a proactive stance on profit-taking. The focus will remain on owning strong businesses and conducting research that challenges consensus views, as several major investments are poised for significant events within the year. Despite declines in market multiples, underlying businesses continue to grow, suggesting a favorable positioning for returns. Additionally, reviewing the Fund's top five holdings could help identify its best picks for 2026.
In its Q2 2026 investor letter, Greenhaven Road Capital highlighted Liquidia Corporation (NASDAQ:LQDA). Liquidia Corporation (NASDAQ:LQDA) is a biopharmaceutical company, focusing on developing therapies for rare cardiopulmonary diseases. On August 14, 2026, Liquidia Corporation (NASDAQ:LQDA) closed at $74.44 per share. One-month return of Liquidia Corporation (NASDAQ:LQDA) was 0.26% and its shares gained 178.79% over the past 52 weeks. Liquidia Corporation (NASDAQ:LQDA) has a market capitalization of $6.66 billion.
Greenhaven Road Capital stated the following regarding Liquidia Corporation (NASDAQ:LQDA) in its Q2 2026 investor letter:
"Liquidia Corporation (NASDAQ:LQDA) — This is another special situation. The company has launched a successful drug but remains in a patent dispute that will determine how large their market can be. We purchased shares below where I believed they would settle even after an adverse trial outcome. The shares appreciated more than 30% before a verdict, so we realized a short-term gain and will revisit the investment after the decision."
Liquidia Corporation (NASDAQ:LQDA) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 41 hedge fund portfolios held Liquidia Corporation (NASDAQ:LQDA) at the end of the first quarter which was 44 in the previous quarter. While we acknowledge the potential of Liquidia Corporation (NASDAQ:LQDA) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#corporation
In its Q2 2026 investor letter, Greenhaven Road Capital highlighted Liquidia Corporation (NASDAQ:LQDA). Liquidia Corporation (NASDAQ:LQDA) is a biopharmaceutical company, focusing on developing therapies for rare cardiopulmonary diseases. On August 14, 2026, Liquidia Corporation (NASDAQ:LQDA) closed at $74.44 per share. One-month return of Liquidia Corporation (NASDAQ:LQDA) was 0.26% and its shares gained 178.79% over the past 52 weeks. Liquidia Corporation (NASDAQ:LQDA) has a market capitalization of $6.66 billion.
Greenhaven Road Capital stated the following regarding Liquidia Corporation (NASDAQ:LQDA) in its Q2 2026 investor letter:
"Liquidia Corporation (NASDAQ:LQDA) — This is another special situation. The company has launched a successful drug but remains in a patent dispute that will determine how large their market can be. We purchased shares below where I believed they would settle even after an adverse trial outcome. The shares appreciated more than 30% before a verdict, so we realized a short-term gain and will revisit the investment after the decision."
Liquidia Corporation (NASDAQ:LQDA) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 41 hedge fund portfolios held Liquidia Corporation (NASDAQ:LQDA) at the end of the first quarter which was 44 in the previous quarter. While we acknowledge the potential of Liquidia Corporation (NASDAQ:LQDA) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#corporation
13 days ago
STATE COLLEGE — The scar runs maybe nine inches down the middle of his chest.
Penn State football quarterback Alex Manske says, truly enough, that he doesn't think about it much. Not when he's running and throwing, like he was during another steamy morning preseason practice this week.
Not when he's constantly studying film and learning from former Iowa State teammate and starting QB Rocco Becht, and his trusted head coach Matt Campbell and offensive coordinator Taylor Mouser.
No matter that the uber-talented redshirt freshman underwent a startling open-heart surgery just five months ago — and appears to be fully recovered and ready for the 2026 season in a couple of weeks, stunningly enough.
His potentially life-altering defect, Manske said, was found during a Penn State-mandated echocardiogram that he and fellow newcomers to the program underwent this past winter. He said he was not aware of any symptoms from his dilated aortic root issue − where the section of the aorta that connects to the heart widens abnormally, increasing the risk of a life-threatening tear or rupture.
#state #alex
Penn State football quarterback Alex Manske says, truly enough, that he doesn't think about it much. Not when he's running and throwing, like he was during another steamy morning preseason practice this week.
Not when he's constantly studying film and learning from former Iowa State teammate and starting QB Rocco Becht, and his trusted head coach Matt Campbell and offensive coordinator Taylor Mouser.
No matter that the uber-talented redshirt freshman underwent a startling open-heart surgery just five months ago — and appears to be fully recovered and ready for the 2026 season in a couple of weeks, stunningly enough.
His potentially life-altering defect, Manske said, was found during a Penn State-mandated echocardiogram that he and fellow newcomers to the program underwent this past winter. He said he was not aware of any symptoms from his dilated aortic root issue − where the section of the aorta that connects to the heart widens abnormally, increasing the risk of a life-threatening tear or rupture.
#state #alex
13 days ago
MackenzieDern believes she needs to improve a lot.
Dern put her Ultimate Fighting Championship strawweight **** le on the linefor the first time against GillianRobertson in the co-main event of UFC330. She outclassed Robertson in every facet to earn aunanimous decision win, but still isn't happy with herperformance.
The strawweight champion believes she needs to work on her cardio,endurance, striking and grappling. While Dern credits Robertson'stoughness, she believes she should have finished her counterpart.According to Dern, her performance might not have sufficed againsta surging contender.
"I'm not happy with my performance," Dern told Ariel Helwani. "Iwish I did better. I wasn't happy with my cardio, my endurance. Iwasn't happy with my striking. I wasn't happy with my grappling. Iwasn't happy. I should have done a lot of that stuff better. Ishould have finished that fight, honestly. Obviously, Gillian isvery tough too… If I fought that performance against someone elsecoming up, that wouldn't be good."
Dern won the vacant **** le against VirnaJandiroba last year after former champ Weili Zhangvacated the **** le and moved up. She is now looking to defend hertitle against Zhang, TatianaSuarez, or LupitaGodinez next.
#performance #needs #cardio
Dern put her Ultimate Fighting Championship strawweight **** le on the linefor the first time against GillianRobertson in the co-main event of UFC330. She outclassed Robertson in every facet to earn aunanimous decision win, but still isn't happy with herperformance.
The strawweight champion believes she needs to work on her cardio,endurance, striking and grappling. While Dern credits Robertson'stoughness, she believes she should have finished her counterpart.According to Dern, her performance might not have sufficed againsta surging contender.
"I'm not happy with my performance," Dern told Ariel Helwani. "Iwish I did better. I wasn't happy with my cardio, my endurance. Iwasn't happy with my striking. I wasn't happy with my grappling. Iwasn't happy. I should have done a lot of that stuff better. Ishould have finished that fight, honestly. Obviously, Gillian isvery tough too… If I fought that performance against someone elsecoming up, that wouldn't be good."
Dern won the vacant **** le against VirnaJandiroba last year after former champ Weili Zhangvacated the **** le and moved up. She is now looking to defend hertitle against Zhang, TatianaSuarez, or LupitaGodinez next.
#performance #needs #cardio
14 days ago
Hayden Panettiere's death follows the loss of her "best friend" and younger brother, Jansen Panettiere, and the fracturing of her relationship with her mother.
The "Scream" actress, who died Aug. 16 after authorities found her "unresponsive" at an apartment complex in South Carolina, heavily struggled with the 2023 death of her brother from cardiomegaly (or an enlarged heart), coupled with aortic valve complications, at age 28.
"He was my only sibling, and it was my job to protect him," Panettiere told People in 2024. "When I lost him, I felt like I lost half of my soul."
In her recent memoir "This Is Me: A Reckoning," Panettiere revealed the former child actor was heavily abusing drugs, including crack and heroin, before he died.
Hayden Panettiere wrote about addiction in book months before death
#jansen
The "Scream" actress, who died Aug. 16 after authorities found her "unresponsive" at an apartment complex in South Carolina, heavily struggled with the 2023 death of her brother from cardiomegaly (or an enlarged heart), coupled with aortic valve complications, at age 28.
"He was my only sibling, and it was my job to protect him," Panettiere told People in 2024. "When I lost him, I felt like I lost half of my soul."
In her recent memoir "This Is Me: A Reckoning," Panettiere revealed the former child actor was heavily abusing drugs, including crack and heroin, before he died.
Hayden Panettiere wrote about addiction in book months before death
#jansen
16 days ago
Sutton Foster wore a plunging, sequin evening gown during a surprise musical performance with her boyfriend Hugh Jackman.
The couple took the stage during a three-day creative retreat hosted by Foster in The Berkshires.
Foster and Jackman confirmed their relationship in January 2025, two years after wrapping their Broadway run of The Music Man in 2023.
Sutton Foster shared a fairy-tale romance moment on stage with Hugh Jackman during a wellness-centered weekend in The Berkshires.
From August 10 to August 13, the Younger star hosted Leading Women: A Sutton Foster Retreat, a three-day creative experience featuring workshops, dance cardio workouts, strength training, and meditation. The sold-out wellness experience, limited to 25 guests, also included an outing at the nearby Tanglewood music festival, where Jackman performed alongside the Boston Pops Orchestra, according to People.
#sutton #music
The couple took the stage during a three-day creative retreat hosted by Foster in The Berkshires.
Foster and Jackman confirmed their relationship in January 2025, two years after wrapping their Broadway run of The Music Man in 2023.
Sutton Foster shared a fairy-tale romance moment on stage with Hugh Jackman during a wellness-centered weekend in The Berkshires.
From August 10 to August 13, the Younger star hosted Leading Women: A Sutton Foster Retreat, a three-day creative experience featuring workshops, dance cardio workouts, strength training, and meditation. The sold-out wellness experience, limited to 25 guests, also included an outing at the nearby Tanglewood music festival, where Jackman performed alongside the Boston Pops Orchestra, according to People.
#sutton #music
19 days ago
It was reported on July 27 that AstraZeneca PLC (NASDAQ:AZN) shares outperformed in European trading after the company reported second-quarter earnings that beat Wall Street expectations and reiterated its full-year 2026 guidance. Core earnings per share (EPS) jumped 18% on a constant exchange rate (FXN) basis year-over-year to $2.63, comfortably ahead of the $2.48 ***** yst consensus. Total revenue reached $15.38 billion, up 5% at constant exchange rates, driven primarily by sustained momentum in its Oncology and Rare Disease units. Management reconfirmed its full-year 2026 outlook of mid-to-high single-digit revenue growth and low double-digit Core EPS growth, expressing confidence in reaching its $80 billion total revenue target by 2030 despite near-term headwind shocks.
The quarter demonstrated strong commercial execution in core growth engines. Oncology revenue rose 16% to $7.33 billion, supported by strong demand for Tagrisso ($1.94 billion), Imfinzi ($1.85 billion), and Enhertu (+31%). Rare Disease contributed $4.9 billion, led by Ultomiris. These gains successfully offset severe pressures in the Cardiovascular, Renal & Metabolism (CVRM) segment, which declined 15% due to the loss of exclusivity (LOE) for Farxiga in the U.S. and ongoing Volume-Based Procurement (VBP) price cuts in China.
Meanwhile, pipeline updates presented a mixed picture. On July 27, AZN disclosed that a Phase 3 study evaluating Ultomiris in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) failed to hit its primary endpoint of event-free survival at week 26 versus placebo. Following the readout, H.C. Wainwright noted that the trial miss represents a "clear positive" for competitor Omeros (OMER), removing a major near-term competitive overhang on its drug Yartemlea and driving Omeros shares up 11% in morning trading.
AstraZeneca PLC (NASDAQ:AZN)'s core profitability remains elite, with core operating margins expanding to 34% in Q2 despite top-line headwinds from generic entry. High gross and net margins signal durable pricing power across its branded specialty portfolio. This strong profitability generates predictable cash flow to fund heavy R&D investments, commercial rollouts, and growing shareholder returns, including a 3-cent increase in the interim dividend to $1.06 per share, while buffering the company against pricing pressure.
The company's expansive late-stage pipeline and high volume of regulatory approvals underpin a multi-year growth trajectory. With 30 major regional approvals since late 2025 and more than 20 high-value trial readouts scheduled over the next 18 months, AZN possesses broad commercial optionality. Continued expansions in oncology (e.g., Enhertu and Imfinzi) and respiratory therapies (such as Breztri and Tezspire) provide direct revenue replacement for legacy products facing patent expiration.
#high #july
The quarter demonstrated strong commercial execution in core growth engines. Oncology revenue rose 16% to $7.33 billion, supported by strong demand for Tagrisso ($1.94 billion), Imfinzi ($1.85 billion), and Enhertu (+31%). Rare Disease contributed $4.9 billion, led by Ultomiris. These gains successfully offset severe pressures in the Cardiovascular, Renal & Metabolism (CVRM) segment, which declined 15% due to the loss of exclusivity (LOE) for Farxiga in the U.S. and ongoing Volume-Based Procurement (VBP) price cuts in China.
Meanwhile, pipeline updates presented a mixed picture. On July 27, AZN disclosed that a Phase 3 study evaluating Ultomiris in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) failed to hit its primary endpoint of event-free survival at week 26 versus placebo. Following the readout, H.C. Wainwright noted that the trial miss represents a "clear positive" for competitor Omeros (OMER), removing a major near-term competitive overhang on its drug Yartemlea and driving Omeros shares up 11% in morning trading.
AstraZeneca PLC (NASDAQ:AZN)'s core profitability remains elite, with core operating margins expanding to 34% in Q2 despite top-line headwinds from generic entry. High gross and net margins signal durable pricing power across its branded specialty portfolio. This strong profitability generates predictable cash flow to fund heavy R&D investments, commercial rollouts, and growing shareholder returns, including a 3-cent increase in the interim dividend to $1.06 per share, while buffering the company against pricing pressure.
The company's expansive late-stage pipeline and high volume of regulatory approvals underpin a multi-year growth trajectory. With 30 major regional approvals since late 2025 and more than 20 high-value trial readouts scheduled over the next 18 months, AZN possesses broad commercial optionality. Continued expansions in oncology (e.g., Enhertu and Imfinzi) and respiratory therapies (such as Breztri and Tezspire) provide direct revenue replacement for legacy products facing patent expiration.
#high #july
25 days ago
Shares of Medtronic (NYSE: MDT), one of the world's largest medical device makers, have declined by more than 30% over the past five years. Higher costs, supply chain bottlenecks, quality control issues, and competitive pressure in surgical robotics all weighed on its stock.
Yet Wall Street remains bullish on Medtronic, with an average price target of $98.44 and a top target of $121. I believe it could rise more than 40% from its current price of $86 and hit that high-end target by the end of this year for a few simple reasons.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Back in March, Medtronic spun off its diabetes unit as MiniMed (NASDAQ: MMED) to streamline its business. It's also restructuring its business to expand its higher-margin cardiovascular and neuroscience portfolios and to integrate more AI features into its surgical planning products.
In fiscal 2026 (which ended in April), Medtronic's revenue grew 8.4% to $36.4 billion (or 5.8% organically) and marked its strongest top-line growth in ten years. From fiscal 2026 to fiscal 2029, **** ysts expect its revenue and EPS to grow at CAGRs of 5% and 13%, respectively.
#NVIDIA #years #surgical
Yet Wall Street remains bullish on Medtronic, with an average price target of $98.44 and a top target of $121. I believe it could rise more than 40% from its current price of $86 and hit that high-end target by the end of this year for a few simple reasons.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Back in March, Medtronic spun off its diabetes unit as MiniMed (NASDAQ: MMED) to streamline its business. It's also restructuring its business to expand its higher-margin cardiovascular and neuroscience portfolios and to integrate more AI features into its surgical planning products.
In fiscal 2026 (which ended in April), Medtronic's revenue grew 8.4% to $36.4 billion (or 5.8% organically) and marked its strongest top-line growth in ten years. From fiscal 2026 to fiscal 2029, **** ysts expect its revenue and EPS to grow at CAGRs of 5% and 13%, respectively.
#NVIDIA #years #surgical
25 days ago
After a year at the helm, Novo Nordisk's CEO Maziar Mike Doustdar's task of closing the gap to pacesetter Eli Lilly doesn't look to be getting any easier.
Doustdar joined Novo at the height of spiralling erosion to rivals in the obesity and type 2 diabetes market segments. While the Danish drugmaker has since gained approval for oral Wegovy, a drug that set a record-breaking pace for a glucagon-like peptide-1 receptor agonist (GLP-1RA) at launch, other pipeline products have had mixed clinical results. Earlier this week, cardiovascular disease drug ziltivekimab failed a Phase III trial, while CagriSema fell short in a non-inferiority trial comparing it to Lilly's tirzepatide.
Coupled with ongoing sales decline, dealmaking presents an obvious avenue in which to boost pipeline offerings. Novo has already said it is actively targeting bolt-on acquisitions, with Doustdar reiterating during the Q2 earnings call that large-scale, transformative deals are still a way off.
"I'm very proud of our internal R&D and pipeline, but no company has a monopoly on good ideas. I've also said we are in every data room to try and see who else has a better idea, who else can give us ******* ets that we can bolt on, and complement what [our internal R&D teams] are doing," Doustdar said.
"I'm a person who never starts with a no to one day [being able to conduct transformative M&A], but you have to be in a very different situation than Novo Nordisk is in today," he added.
#pipeline
Doustdar joined Novo at the height of spiralling erosion to rivals in the obesity and type 2 diabetes market segments. While the Danish drugmaker has since gained approval for oral Wegovy, a drug that set a record-breaking pace for a glucagon-like peptide-1 receptor agonist (GLP-1RA) at launch, other pipeline products have had mixed clinical results. Earlier this week, cardiovascular disease drug ziltivekimab failed a Phase III trial, while CagriSema fell short in a non-inferiority trial comparing it to Lilly's tirzepatide.
Coupled with ongoing sales decline, dealmaking presents an obvious avenue in which to boost pipeline offerings. Novo has already said it is actively targeting bolt-on acquisitions, with Doustdar reiterating during the Q2 earnings call that large-scale, transformative deals are still a way off.
"I'm very proud of our internal R&D and pipeline, but no company has a monopoly on good ideas. I've also said we are in every data room to try and see who else has a better idea, who else can give us ******* ets that we can bolt on, and complement what [our internal R&D teams] are doing," Doustdar said.
"I'm a person who never starts with a no to one day [being able to conduct transformative M&A], but you have to be in a very different situation than Novo Nordisk is in today," he added.
#pipeline
26 days ago
Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, the Fund appreciated 10.61% on an annualized basis, compared with 10.02% for the Benchmark and 14.83% for the Index. Strong stock selection in pharmaceuticals, biotechnology, health care equipment, and life sciences tools and services supported the Fund's outperformance, although limited exposure to managed care stocks reduced relative returns. The Fund remains positive on health care due to improving biotechnology funding, strong acquisition activity, recovering managed care margins, and growth from an aging population, chronic disease, medical innovation, and higher health care spending. In addition, please check the Fund's top five holdings to know the best picks in 2026.
In its second-quarter 2026 investor letter, Baron Health Care Fund highlighted Edwards Lifesciences Corporation (NYSE:EW). Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company that provides products and technologies to treat advanced cardiovascular diseases. On August 3, 2026, Edwards Lifesciences Corporation (NYSE:EW) closed at $88.82 per share. The one-month return of Edwards Lifesciences Corporation (NYSE:EW) was -6.33% and its shares gained 12.09% over the past 52 weeks. Edwards Lifesciences Corporation (NYSE:EW) has a market capitalization of $51.14 billion.
Baron Health Care Fund stated the following regarding Edwards Lifesciences Corporation (NYSE:EW) in its Q2 2026 investor letter:
"Edwards Lifesciences Corporation (NYSE:EW) was a material tailwind in the period. Shares of Edwards, a medical technology company specializing in structural heart disease therapies, rose due to solid first quarter results and an updated Medicare coverage decision for transcatheter aortic valve replacement (TAVR), which has the potential to increase procedure volumes. We retain conviction as Edwards' lead in replacement therapies for mitral and tricuspid valves, which combined with a total addressable market that could approach the scale of core TAVR provides a durable and differentiated growth runway that competitors are years away from replicating."
Edwards Lifesciences Corporation (NYSE:EW) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 68 hedge fund portfolios held Edwards Lifesciences Corporation (NYSE:EW) at the end of the first quarter which was 64 in the previous quarter. While we acknowledge the potential of Edwards Lifesciences Corporation (NYSE:EW) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tarif
In its second-quarter 2026 investor letter, Baron Health Care Fund highlighted Edwards Lifesciences Corporation (NYSE:EW). Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company that provides products and technologies to treat advanced cardiovascular diseases. On August 3, 2026, Edwards Lifesciences Corporation (NYSE:EW) closed at $88.82 per share. The one-month return of Edwards Lifesciences Corporation (NYSE:EW) was -6.33% and its shares gained 12.09% over the past 52 weeks. Edwards Lifesciences Corporation (NYSE:EW) has a market capitalization of $51.14 billion.
Baron Health Care Fund stated the following regarding Edwards Lifesciences Corporation (NYSE:EW) in its Q2 2026 investor letter:
"Edwards Lifesciences Corporation (NYSE:EW) was a material tailwind in the period. Shares of Edwards, a medical technology company specializing in structural heart disease therapies, rose due to solid first quarter results and an updated Medicare coverage decision for transcatheter aortic valve replacement (TAVR), which has the potential to increase procedure volumes. We retain conviction as Edwards' lead in replacement therapies for mitral and tricuspid valves, which combined with a total addressable market that could approach the scale of core TAVR provides a durable and differentiated growth runway that competitors are years away from replicating."
Edwards Lifesciences Corporation (NYSE:EW) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 68 hedge fund portfolios held Edwards Lifesciences Corporation (NYSE:EW) at the end of the first quarter which was 64 in the previous quarter. While we acknowledge the potential of Edwards Lifesciences Corporation (NYSE:EW) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tarif
26 days ago
AstraZeneca (AZN) stock took a nosedive Monday amid reports it's mulling a megamerger with Bristol Myers Squibb (BMY).
The combined company would be worth roughly $400 billion, "making it one of the biggest pharmaceutical mergers in history," RBC Capital Markets ******* yst Trung Huynh said in a report. The Financial Times first reported the early merger talks. AstraZeneca declined to comment to Investor's Business Daily. Bristol Myers didn't immediately respond.
The deal would merge two oncology powerhouses, and likely trigger an antitrust review. Bristol Myers fills portfolio gaps in blood cancer, immunology, cardiovascular diseases and central nervous system conditions where AstraZeneca lacks scale today, Huynh said.
AstraZeneca stock tumbled 6.9% to 157.97. Shares are already trading below their 21-day, 50-day and 200-day moving averages. Bristol Myers Squibb stock, on the other hand, inched a fraction higher to 65.47. The stock ended the regular session in a buy zone that runs up to 66.03.
Given the size of the two companies, the deal would likely be mostly stock-based, resulting in Bristol Myers shareholders owning roughly a third of the combined company, William Blair ******* yst Matt Phipps said in a client note. He says $160 billion makes sense as a price tag for Bristol Myers Squibb.
#astrazeneca #huynh #combined
The combined company would be worth roughly $400 billion, "making it one of the biggest pharmaceutical mergers in history," RBC Capital Markets ******* yst Trung Huynh said in a report. The Financial Times first reported the early merger talks. AstraZeneca declined to comment to Investor's Business Daily. Bristol Myers didn't immediately respond.
The deal would merge two oncology powerhouses, and likely trigger an antitrust review. Bristol Myers fills portfolio gaps in blood cancer, immunology, cardiovascular diseases and central nervous system conditions where AstraZeneca lacks scale today, Huynh said.
AstraZeneca stock tumbled 6.9% to 157.97. Shares are already trading below their 21-day, 50-day and 200-day moving averages. Bristol Myers Squibb stock, on the other hand, inched a fraction higher to 65.47. The stock ended the regular session in a buy zone that runs up to 66.03.
Given the size of the two companies, the deal would likely be mostly stock-based, resulting in Bristol Myers shareholders owning roughly a third of the combined company, William Blair ******* yst Matt Phipps said in a client note. He says $160 billion makes sense as a price tag for Bristol Myers Squibb.
#astrazeneca #huynh #combined
1 month ago
Medicare Advantage enrollment is easy, but switching back requires medical underwriting that a stent, GLP-1 prescription, or high blood pressure can permanently block.
Federal law gives Medigap applicants one guaranteed-issue window: six months starting at 65 with Part B enrollment; after that, carriers can legally deny you.
Original Medicare without a supplement carries a $1,736 per-benefit-period hospital deductible and unlimited 20% Part B coinsurance with no annual out-of-pocket cap.
Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don't waste another minute; learn more here.
A 71-year-old Florida widow had spent two years fighting her Medicare Advantage plan over a cardiology referral. She finally decided she was done. A broker helped her choose Medigap Plan G and start the application. Then the insurer saw the stent placed in 2023 and declined her. Other carriers followed. She was allowed to leave Medicare Advantage. Buying the coverage she wanted on the other side was the problem.
#medicare #advantage #medigap #stent
Federal law gives Medigap applicants one guaranteed-issue window: six months starting at 65 with Part B enrollment; after that, carriers can legally deny you.
Original Medicare without a supplement carries a $1,736 per-benefit-period hospital deductible and unlimited 20% Part B coinsurance with no annual out-of-pocket cap.
Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don't waste another minute; learn more here.
A 71-year-old Florida widow had spent two years fighting her Medicare Advantage plan over a cardiology referral. She finally decided she was done. A broker helped her choose Medigap Plan G and start the application. Then the insurer saw the stent placed in 2023 and declined her. Other carriers followed. She was allowed to leave Medicare Advantage. Buying the coverage she wanted on the other side was the problem.
#medicare #advantage #medigap #stent
1 month ago
Good news: Joan Laporta's is back in action after a few days' rest following a medical procedure.
The FC Barcelona club president had to undergo surgery to fix a cardiac arrhythmia — that is, an irregular heartbeat — on Tuesday. Doctors used a defibrillation procedure, essentially using controlled electrical impulses to shock his heart back into a normal rhythm.
Afterwards, he had to take a few days off to recover. On Friday, he's been officially cleared to return to work.
Laporta celebrated on Instagram: "I've been discharged! Heading home!"
The president thanked the Hospital de Barcelona, including the Emergency, ICU, Laboratory, Anesthesiology, Cardiology, Radiology, and Endoscopy departments and several specific doctors by name.
#Barcelona #doctors #days
The FC Barcelona club president had to undergo surgery to fix a cardiac arrhythmia — that is, an irregular heartbeat — on Tuesday. Doctors used a defibrillation procedure, essentially using controlled electrical impulses to shock his heart back into a normal rhythm.
Afterwards, he had to take a few days off to recover. On Friday, he's been officially cleared to return to work.
Laporta celebrated on Instagram: "I've been discharged! Heading home!"
The president thanked the Hospital de Barcelona, including the Emergency, ICU, Laboratory, Anesthesiology, Cardiology, Radiology, and Endoscopy departments and several specific doctors by name.
#Barcelona #doctors #days
1 month ago
Chelsea FC winger Mykhailo Mudryk has been cleared to make an immediate return to action after the Court of Arbitration for Sport (Cas) partially upheld an appeal against his four-year ban for doping.
The 25-year-old has not played a competitive match since November 2024 after returning an adverse finding for banned substance meldonium.
Having been provisionally suspended by the Football ****** ociation (FA), Mudryk was then widely reported to have been given a four-year ban – though appealed to Cas against that decision.
The body has now ruled that Mudryk can return "with immediate effect" after he accepted breaking anti-doping rules, and reached agreement on a suspension equivalent to time served.
Cas said the test displayed "a low concentration" of the prohibited substance. It added that changes have since been made to the World Anti-Doping Agency (Wada) technical document regarding meldonium, a cardiovascular medication.
#year
The 25-year-old has not played a competitive match since November 2024 after returning an adverse finding for banned substance meldonium.
Having been provisionally suspended by the Football ****** ociation (FA), Mudryk was then widely reported to have been given a four-year ban – though appealed to Cas against that decision.
The body has now ruled that Mudryk can return "with immediate effect" after he accepted breaking anti-doping rules, and reached agreement on a suspension equivalent to time served.
Cas said the test displayed "a low concentration" of the prohibited substance. It added that changes have since been made to the World Anti-Doping Agency (Wada) technical document regarding meldonium, a cardiovascular medication.
#year
1 month ago
Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. With a market cap of $129.9 billion, the company offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas.
Shares of BMY have rallied the broader market over the past year, surging 33.9% compared to the S&P 500 Index's ($SPX) 16.3% surge. Moreover, in 2026, the stock has risen by nearly 17.9%, outpacing the SPX's 8.5% gain.
Dear Sandisk Stock Fans, Mark Your Calendars for August 5
Nasdaq Futures Plunge as Chip Selloff Rages On, FOMC Meeting and Earnings on Tap
Ahead of Microsoft Earnings, Here's What Barchart Data Says Comes Next for MSFT Stock
#products #bristol #squibb
Shares of BMY have rallied the broader market over the past year, surging 33.9% compared to the S&P 500 Index's ($SPX) 16.3% surge. Moreover, in 2026, the stock has risen by nearly 17.9%, outpacing the SPX's 8.5% gain.
Dear Sandisk Stock Fans, Mark Your Calendars for August 5
Nasdaq Futures Plunge as Chip Selloff Rages On, FOMC Meeting and Earnings on Tap
Ahead of Microsoft Earnings, Here's What Barchart Data Says Comes Next for MSFT Stock
#products #bristol #squibb
1 month ago
An estimated 21.5 million additional adults in the United States may now be eligible for statins under updated cholesterol treatment guidelines, according to a new study.
The researchers aimed to estimate how many adults in the US would be considered eligible for statin therapy under the new 2026 blood cholesterol guidelines issued by the American Heart **** ociation, the American College of Cardiology and nine partnering medical societies, compared with the previous 2018 guidelines.
The **** ysis, published July 20 in the journal JAMA, found that the changes could bring the total number of Americans eligible for statins, medications that lower cholesterol, to about 87.5 million people, or more than half of adults ages 30 to 79.
What prompted this major expansion, and does being eligible mean that someone should immediately begin taking medication? To help us understand the study and what patients should discuss with their healthcare providers, I spoke with CNN wellness expert Dr. Leana Wen. Wen is an emergency physician and clinical **** ociate professor at George Washington University. She previously served as Baltimore's health commissioner.
CNN: Who are the millions of Americans who are newly eligible for statins and why?
#statins #cholesterol
The researchers aimed to estimate how many adults in the US would be considered eligible for statin therapy under the new 2026 blood cholesterol guidelines issued by the American Heart **** ociation, the American College of Cardiology and nine partnering medical societies, compared with the previous 2018 guidelines.
The **** ysis, published July 20 in the journal JAMA, found that the changes could bring the total number of Americans eligible for statins, medications that lower cholesterol, to about 87.5 million people, or more than half of adults ages 30 to 79.
What prompted this major expansion, and does being eligible mean that someone should immediately begin taking medication? To help us understand the study and what patients should discuss with their healthcare providers, I spoke with CNN wellness expert Dr. Leana Wen. Wen is an emergency physician and clinical **** ociate professor at George Washington University. She previously served as Baltimore's health commissioner.
CNN: Who are the millions of Americans who are newly eligible for statins and why?
#statins #cholesterol
1 month ago
The cause of death for MJ Shannon has been released
Her immediate cause of death is reportedly listed as acute cardiopulmonary arrest
MJ died on Thursday, July 16, at the age of 91, Kris Jenner previously announced
Kris Jenner's mom Mary Jo "MJ" Shannon's official cause of death has been determined.
MJ died on July 16, at age 91. According to her death certificate, obtained by Us Weekly on Tuesday, July 28, her immediate cause of death was acute cardiopulmonary arrest.
#cause #immediate #acute #arrest
Her immediate cause of death is reportedly listed as acute cardiopulmonary arrest
MJ died on Thursday, July 16, at the age of 91, Kris Jenner previously announced
Kris Jenner's mom Mary Jo "MJ" Shannon's official cause of death has been determined.
MJ died on July 16, at age 91. According to her death certificate, obtained by Us Weekly on Tuesday, July 28, her immediate cause of death was acute cardiopulmonary arrest.
#cause #immediate #acute #arrest
1 month ago
Indianapolis, Indiana-based Eli Lilly and Company (LLY) is a leading pharmaceutical company that sells Trulicity, Verzenio and Taltz drugs. The company discovers, develops, and markets human pharmaceuticals. With a market cap of $1.1 trillion, LLY's products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products. The pharmaceutical giant is expected to announce its fiscal second-quarter earnings for 2026 before the market opens on Wednesday, Aug. 5.
Ahead of the event, ****** ysts expect LLY to report a profit of $7.47 per share on a diluted basis, up 18.4% from $6.31 per share in the year-ago quarter. The company has consistently surpassed Wall Street's EPS estimates in its last four quarterly reports.
PayPal Says a $53 Billion Takeover Offer from Stripe Undervalues It. How to Play PYPL Stock Here.
Billionaire Jeff Bezos Called Amazon's Customer Service to Prove a Point But Waited in Silence for More Than 10 Minutes — 'It Was Really Long'
Micron Stock Is Near Bear-Market Territory. Here's Why ASML's Guidance Says Buy the Dip.
#indiana
Ahead of the event, ****** ysts expect LLY to report a profit of $7.47 per share on a diluted basis, up 18.4% from $6.31 per share in the year-ago quarter. The company has consistently surpassed Wall Street's EPS estimates in its last four quarterly reports.
PayPal Says a $53 Billion Takeover Offer from Stripe Undervalues It. How to Play PYPL Stock Here.
Billionaire Jeff Bezos Called Amazon's Customer Service to Prove a Point But Waited in Silence for More Than 10 Minutes — 'It Was Really Long'
Micron Stock Is Near Bear-Market Territory. Here's Why ASML's Guidance Says Buy the Dip.
#indiana
1 month ago
Fred Alger Management, an investment management company, released its "Alger Weatherbie Specialized Growth Fund" second-quarter 2026 investor letter. A copy of the letter can be downloaded here. U.S. equities experienced a strong recovery in Q2 2026, with the S&P 500 Index gaining 15.2%, marking its best quarter since 2020. A ceasefire between the United States and Iran and accelerated investment in artificial intelligence (AI) regained market optimism in the quarter, leading the Information Technology and Industrials sectors upward, and Energy and Utilities lagged because of falling oil and gas prices. In June, the Federal Reserve maintained steady interest rates, but the meeting had a hawkish tone. As AI transitions into its agentic phase, opportunities are identified within sectors adopting the technology. The Weatherbie Specialized Growth Fund's Class A shares outperformed the Russell 2500 Growth Index in the quarter. The Industrials and Information Technology sectors contributed to the relative performance, whereas Financials and Consumer Discretionary sectors detracted. In addition, please check the Fund's top five holdings to know its best picks in 2026.
In its Q2 2026 investor letter, Alger Weatherbie Specialized Growth Fund highlighted Artivion, Inc. (NYSE:AORT). Artivion, Inc. (NYSE:AORT) is a global manufacturer and distributor of medical devices and implantable human tissues. On July 20, 2026, Artivion, Inc. (NYSE:AORT) closed at $25.37 per share. One-month return of Artivion, Inc. (NYSE:AORT) was 22.68%, and its shares lost 16.55% over the past 52 weeks. Artivion, Inc. (NYSE:AORT) has a market capitalization of $1.23 billion.
Alger Weatherbie Specialized Growth Fund stated the following regarding Artivion, Inc. (NYSE:AORT) in its Q2 2026 investor update:
"Artivion, Inc. (NYSE:AORT) manufactures, processes, and distributes medical devices and implantable human tissues used in cardiac and vascular surgical procedures, with a focus on treating patients with aortic disease. The company's portfolio includes established products as well as newer technologies designed to improve outcomes in complex cardiovascular procedures. During the quarter, shares detracted from performance after the company reported in-line first-quarter results but modestly lowered its full-year outlook, primarily due to slower-than-expected starter set sales for AMDS, its key new product cycle."
Artivion, Inc. (NYSE:AORT) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 28 hedge fund portfolios held Artivion, Inc. (NYSE:AORT) at the end of the first quarter, up from 25 in the previous quarter. Artivion, Inc. (NYSE:AORT) delivered total revenue of $116.3 million in Q1 2026, an increase of 12% on a non-GAAP constant currency basis. While we acknowledge the potential of Artivion, Inc. (NYSE:AORT) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If y
In its Q2 2026 investor letter, Alger Weatherbie Specialized Growth Fund highlighted Artivion, Inc. (NYSE:AORT). Artivion, Inc. (NYSE:AORT) is a global manufacturer and distributor of medical devices and implantable human tissues. On July 20, 2026, Artivion, Inc. (NYSE:AORT) closed at $25.37 per share. One-month return of Artivion, Inc. (NYSE:AORT) was 22.68%, and its shares lost 16.55% over the past 52 weeks. Artivion, Inc. (NYSE:AORT) has a market capitalization of $1.23 billion.
Alger Weatherbie Specialized Growth Fund stated the following regarding Artivion, Inc. (NYSE:AORT) in its Q2 2026 investor update:
"Artivion, Inc. (NYSE:AORT) manufactures, processes, and distributes medical devices and implantable human tissues used in cardiac and vascular surgical procedures, with a focus on treating patients with aortic disease. The company's portfolio includes established products as well as newer technologies designed to improve outcomes in complex cardiovascular procedures. During the quarter, shares detracted from performance after the company reported in-line first-quarter results but modestly lowered its full-year outlook, primarily due to slower-than-expected starter set sales for AMDS, its key new product cycle."
Artivion, Inc. (NYSE:AORT) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 28 hedge fund portfolios held Artivion, Inc. (NYSE:AORT) at the end of the first quarter, up from 25 in the previous quarter. Artivion, Inc. (NYSE:AORT) delivered total revenue of $116.3 million in Q1 2026, an increase of 12% on a non-GAAP constant currency basis. While we acknowledge the potential of Artivion, Inc. (NYSE:AORT) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If y
1 month ago
Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need. Valued at $166.7 billion by market cap, the company's primary areas of focus include HIV, AIDS, liver disease, and serious cardiovascular and respiratory conditions. The HIV giant is expected to announce its fiscal second-quarter earnings for 2026 in the near term.
Ahead of the event, ******* ysts expect GILD to report a loss of $7.09 per share on a diluted basis, down 452.7% from a profit of $2.01 per share in the year-ago quarter. The company has consistently surpassed the consensus estimates in each of the last four quarters.
Huge, Unusual Intel Options Volume Today Ahead of Earnings This Week
Intel Stock Is Down, But Put Premiums are High - Put Short Sellers Love the High Yields
The Number Tesla Stock Bulls Are Really Waiting for This Earnings Season Has Nothing to Do With Cars
#earnings
Ahead of the event, ******* ysts expect GILD to report a loss of $7.09 per share on a diluted basis, down 452.7% from a profit of $2.01 per share in the year-ago quarter. The company has consistently surpassed the consensus estimates in each of the last four quarters.
Huge, Unusual Intel Options Volume Today Ahead of Earnings This Week
Intel Stock Is Down, But Put Premiums are High - Put Short Sellers Love the High Yields
The Number Tesla Stock Bulls Are Really Waiting for This Earnings Season Has Nothing to Do With Cars
#earnings
1 month ago
Kai Trump stunned fans after revealing her washboard abs during a paddleboarding outing with her aunt, Ivanka Trump, in July, and the 19-year-old shared just how she achieved the six-pack look. Kai, who will begin her freshman year at the University of Miami in the coming weeks, revealed that undergoing wrist surgery gave her the ****** e to focus on her fitness and spend more time in the gym.
After sustaining injuries from playing competitive golf, Kai was forced to undergo surgery to repair a tendon in her wrist in January. While she couldn't pick up a golf club during her recovery, she could work out in the gym and informed her friends of her new goal.
"I literally told them, 'I have seven months before I return to golf, we're getting a six-pack,'" she shared with Fox News Digital. "And I got a six-pack literally just by prioritizing the right foods and working out."
Kai sticks to an intense workout regimen (Instagram)
In the gym, the social media star focuses on core exercises, squats and cardio, and favors the stair-climbing machine to build stamina. Kai also explained that working out had the added benefit of helping her mental wellbeing as well as her physical health.
#golf #surgery #working #ivanka
After sustaining injuries from playing competitive golf, Kai was forced to undergo surgery to repair a tendon in her wrist in January. While she couldn't pick up a golf club during her recovery, she could work out in the gym and informed her friends of her new goal.
"I literally told them, 'I have seven months before I return to golf, we're getting a six-pack,'" she shared with Fox News Digital. "And I got a six-pack literally just by prioritizing the right foods and working out."
Kai sticks to an intense workout regimen (Instagram)
In the gym, the social media star focuses on core exercises, squats and cardio, and favors the stair-climbing machine to build stamina. Kai also explained that working out had the added benefit of helping her mental wellbeing as well as her physical health.
#golf #surgery #working #ivanka
1 month ago
Cathie Wood's ARK Genomic Revolution ETF (NYSEMKT: ARKG) focuses on companies in the genomics sector, especially in healthcare. Since the beginning of July, Wood has, through this Ark Invest exchange-traded fund (ETF), bought $15.3 million worth of Ionis Pharmaceuticals (NASDAQ: IONS), a biotech company based in Carlsbad, California.
The stock is down nearly 37% from its 2026 high earlier this month, with much of that decline coming after it and its partner AstraZeneca announced a surprise late-stage trial failure regarding eplontersen, a medicine used to treat patients with transthyretin amyloidosis cardiomyopathy, or ATTR-CM, a rare heart disease. All of Wood's recent Ionis purchases came after that announcement, suggesting she is taking advantage of the stock's decline to buy more shares while maintaining a long-term view that the company is worth investing in.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Let's see what she may be seeing.
In June 2026, the Food and Drug Administration (FDA) approved Ionis's drug Tryngolza (olezarsen) for treatment of severe hypertriglyceridemia (sHTG), a condition characterized by elevated blood triglyceride levels. Tryngolza's initial approval in 2024 was for familial chylomicronemia syndrome (FCS), a rare disease that causes high levels of triglycerides in the blood. FCS affects only about 3,000 people in the U.S., but the new sHTG approval expands its target market to more than 3 million potential patients in the U.S. alone.
The stock is down nearly 37% from its 2026 high earlier this month, with much of that decline coming after it and its partner AstraZeneca announced a surprise late-stage trial failure regarding eplontersen, a medicine used to treat patients with transthyretin amyloidosis cardiomyopathy, or ATTR-CM, a rare heart disease. All of Wood's recent Ionis purchases came after that announcement, suggesting she is taking advantage of the stock's decline to buy more shares while maintaining a long-term view that the company is worth investing in.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Let's see what she may be seeing.
In June 2026, the Food and Drug Administration (FDA) approved Ionis's drug Tryngolza (olezarsen) for treatment of severe hypertriglyceridemia (sHTG), a condition characterized by elevated blood triglyceride levels. Tryngolza's initial approval in 2024 was for familial chylomicronemia syndrome (FCS), a rare disease that causes high levels of triglycerides in the blood. FCS affects only about 3,000 people in the U.S., but the new sHTG approval expands its target market to more than 3 million potential patients in the U.S. alone.
1 month ago
Veteran Democratic strategist James Carville said Wednesday that while he takes no joy in the late Senator Lindsay Graham's death, he will remember his career as one of "duplicity."
"Let's give him all the credit in the world. He was one of the [Bill Clinton] impeachment managers. Remember the great moral ***** an Henry Hyde and that whole crowd. And yeah, he was a little bit more than just for impeachment. He was the most aggressive," Carville said.
"I knew him. He could be personable, but I don't think the man has had a... sorry, I don't want anybody to get sick or die, that's not it," Carville said. "But I think his political career is mostly defined by duplicity. Just my own view."
Graham, 71, died Saturday night from an aortic dissection due to arteriosclerotic cardiovascular disease. The news stunned Washington, as Graham was one of the body's most active members and was even scheduled to appear on NBC's "Meet the Press" Sunday morning.
Media Ghouls, Commentators Across Political Aisle Mock Lindsey Graham's Death With 'Good Riddance' Posts
"Let's give him all the credit in the world. He was one of the [Bill Clinton] impeachment managers. Remember the great moral ***** an Henry Hyde and that whole crowd. And yeah, he was a little bit more than just for impeachment. He was the most aggressive," Carville said.
"I knew him. He could be personable, but I don't think the man has had a... sorry, I don't want anybody to get sick or die, that's not it," Carville said. "But I think his political career is mostly defined by duplicity. Just my own view."
Graham, 71, died Saturday night from an aortic dissection due to arteriosclerotic cardiovascular disease. The news stunned Washington, as Graham was one of the body's most active members and was even scheduled to appear on NBC's "Meet the Press" Sunday morning.
Media Ghouls, Commentators Across Political Aisle Mock Lindsey Graham's Death With 'Good Riddance' Posts
2 months ago
Lexeo Therapeutics Inc. (NASDAQ:LXEO) is one of the 10 best stocks under $10 that could triple.
On June 15, Lexeo Therapeutics Inc. (NASDAQ:LXEO) disclosed that it has finalized the critical trial protocol of SUNRISE-FA 2. The company also finalized the statistical ***** ysis plan meant to offer clinical evidence for submission of a Biologics License Application to the U.S. FDA.
Pressmaster/Shutterstock.com
The company highlighted that this submission is for the gene-based therapy candidate, LX2006, under the 2028 approval pathway. Lexeo's Chief Medical Officer, Narinder Bhalla, M.D., labeled it as a major stride that involves the completion of a critical study design for SUNRISE-FA 2. He believes that it sets a path to ***** s LX2006 in Friedreich's ataxia cardiomyopathy. He further stated:
"Patients living with FA, particularly those with cardiac involvement, have a significant unmet need for new treatment options and remain at the center of our efforts. This progress brings us one step closer to delivering a potential new therapy, and we remain focused on execution as we work to initiate the pivotal study and enroll the first patient by the end of the month."
On June 15, Lexeo Therapeutics Inc. (NASDAQ:LXEO) disclosed that it has finalized the critical trial protocol of SUNRISE-FA 2. The company also finalized the statistical ***** ysis plan meant to offer clinical evidence for submission of a Biologics License Application to the U.S. FDA.
Pressmaster/Shutterstock.com
The company highlighted that this submission is for the gene-based therapy candidate, LX2006, under the 2028 approval pathway. Lexeo's Chief Medical Officer, Narinder Bhalla, M.D., labeled it as a major stride that involves the completion of a critical study design for SUNRISE-FA 2. He believes that it sets a path to ***** s LX2006 in Friedreich's ataxia cardiomyopathy. He further stated:
"Patients living with FA, particularly those with cardiac involvement, have a significant unmet need for new treatment options and remain at the center of our efforts. This progress brings us one step closer to delivering a potential new therapy, and we remain focused on execution as we work to initiate the pivotal study and enroll the first patient by the end of the month."
